MedTrace Logo

Study to Assess the Pharmacokinetics of GSK1278863A Coadministered With a High Fat Meal or an Inhibitor of CYP2C8 (Gemfibrozil)

NCT01376232 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2017-06-09

No results posted yet for this study

Summary

Study to Assess the Pharmacokinetics of GSK1278863A Coadministered with a High Fat Meal or an Inhibitor of CYP2C8 (gemfibrozil),\]

Conditions

  • Anaemia

Interventions

DRUG

GSK1278863

GSk1278863 100mg

DRUG

GSK1278863 + food

High Fat meal + 100 mg GSK1278863

DRUG

Gemfibrozil

600 mg Gemfibrozil

Sponsors & Collaborators

  • Octagon Research Solutions, Incoporated

    collaborator UNKNOWN

  • GlaxoSmithKline

    lead INDUSTRY

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-11-08
Primary Completion
2010-12-20
Completion
2010-12-20

Countries

  • India

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01376232 on ClinicalTrials.gov